You are here

Victoza® (liraglutide 1.8 mg) provided superior HbA1c reductions in adults with type 2 diabetes compared to continued sitagliptin treatment

Read the full release

Boston, US, 2 April 2016 - Findings from a clinical trial comparing Victoza® (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from sitagliptin to Victoza® provided superior HbA1c reductions vs continuing with sitagliptin treatment in adults with type 2 diabetes. Results from the LIRA-SWITCH trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US.1

Further information

Media:  
Katrine Sperling+45 4442 6718 krsp@novonordisk.com
Åsa Josefsson+45 3079 7708aajf@novonordisk.com

Investors:
  
Peter Hugreffe Ankersen+45 3075 9085phak@novonordisk.com
Daniel Bohsen+45 3079 6376dabo@novonordisk.com
Melanie Raouzeos+45 3075 3479mrz@novonordisk.com
Kasper Veje+45 3079 8519kpvj@novonordisk.com

Attachment

Sunday, November 4, 2018 - 18:41